Kisspeptin Dosage Chart & Schedule Guide.

No, and the difference matters more than almost anywhere else in peptides. Kisspeptin-10 is the active C-terminal 10 amino acids of kisspeptin-54 (metastin), so the receptor pharmacology is the same, but the plasma half-life is roughly 4 minutes versus 27.6 minutes. Matched molar IV infusions produce comparable gonadotrophin responses, even though kisspeptin-54 reaches up to 37-fold higher circulating levels. Critically, nearly every headline human result attributed to "kisspeptin" used kisspeptin-54: the sexual brain-processing and HSDD trials, the IVF oocyte-maturation trigger work, the 8-week hypothalamic amenorrhoea study, and all the successful subcutaneous dosing. Kisspeptin-10 is the cheaper, shorter-acting molecule, and it is not a drop-in substitute.

In men whose problem is upstream (low LH driving low testosterone), yes, modestly, and only while dosing. An 11-hour IV infusion in men with type 2 diabetes and mild hypogonadism took testosterone from 8.5 to 11.4 nmol/L, and a 22.5-hour infusion in healthy men moved it from 16.6 to 24.0 nmol/L. Both needed continuous infusion. If your testes cannot respond (primary hypogonadism, prior injury, Klinefelter’s) or you are already on exogenous testosterone, kisspeptin has nothing to push on and will do essentially nothing. Get LH, FSH, total and free testosterone, prolactin and SHBG measured before you decide this is your problem.

There is no human trial of kisspeptin-10 for HPG-axis restart, so anyone offering you a validated restart protocol is ahead of the data. Mechanistically it sits above GnRH, so it needs an intact hypothalamus, pituitary and testes to work; hCG bypasses that whole chain and acts directly on the Leydig cell, which is why it is the tool with actual evidence behind it. On TRT it is the least promising option of all: exogenous testosterone suppresses at the level of the hypothalamus and pituitary, which is precisely the machinery kisspeptin would have to work through. Talk to a physician about hCG, enclomiphene or an SERM protocol instead.

Because the KISS1R receptor does not tolerate continuous stimulation. Twice-daily kisspeptin-54 in women with hypothalamic amenorrhoea caused LH responsiveness to fade progressively and FSH responsiveness to be nearly abolished by day two, whereas twice-weekly dosing produced only partial desensitisation and sustained hormone release over eight weeks. The extreme version proves the point: TAK-448, a kisspeptin analogue formulated for sustained exposure, drove testosterone into the castration range and was developed as a prostate cancer drug. Pulsatile, intermittent dosing is not a conservative preference here; it is the mechanism.

More than you would use for most peptides, and yes it matters a lot. Doses here are 50 – 100 mcg, which is tiny. A 5 mg vial in 2.5 mL of bacteriostatic water gives 2,000 mcg/mL, so 100 mcg is 5 units on a U-100 insulin syringe and 50 mcg is 2.5 units. If you instead reconstitute a 10 mg vial in 1 mL, 100 mcg becomes 1 unit, where a half-unit misread is a 50% dosing error. Use the most water your vial will physically hold, keep the mixed vial in the fridge, and use it within about four weeks. The extra diluent costs nothing and the accuracy is free.

The best human evidence is genuinely encouraging but does not describe what you would be doing. In a placebo-controlled crossover trial in men with hypoactive sexual desire disorder, kisspeptin-54 infused intravenously at 1 nmol/kg/h for 75 minutes modulated activity in sexual-processing brain regions and increased penile tumescence to visual sexual stimuli by up to 56% versus placebo. That is a real result with a real control group. But it is a different molecule, a different route, and an acute effect measured inside the study session; it is not evidence that weekly subcutaneous kisspeptin-10 improves desire over time, and no trial has tested that.

Dramatically, and the difference is not subtle. Healthy women in the follicular phase showed no gonadotrophin response to kisspeptin-10 at all: not to IV bolus up to 10 nmol/kg, not to subcutaneous bolus up to 32 nmol/kg, not to IV infusion. In the preovulatory phase, the same IV bolus raised both LH and FSH. Post-menopausal women are more responsive than cycling women, and women on hormonal contraception respond minimally. The response tracks baseline oestradiol closely: in one subcutaneous kisspeptin-54 study, a 100 pmol/L higher baseline oestradiol predicted about 1.0 IU/L more LH response. In practice, where a woman is in her cycle changes the answer more than the dose does.

No, on both counts. Kisspeptin-10 is not an approved drug in any jurisdiction. FDA’s Pharmacy Compounding Advisory Committee reviewed it on 29 October 2024 and voted against adding it to the 503A bulks list (alongside ipamorelin, ibutamoren and L-theanine), citing insufficient human safety data and inadequate efficacy evidence, so US compounding pharmacies cannot legally use it. It was also not among the twelve peptides (BPC-157, TB-500, Epitalon and others) that FDA removed from Category 2 in April 2026. Everything on the market is sold "for research use only", which means nobody is verifying identity, purity or sterility on your behalf; third-party testing is on you.